Due to a production error, there was an error in affiliation 4. Instead of “Department of Foundation, Georgetown, Pulau Pinang, Malaysia,” it should be “Department of Foundation, RCSI & UCD Malaysia Campus, George Town, Pulau Pinang, Malaysia.”
The publisher apologizes for this mistake. The original version of this article has been updated.
Summary
Keywords
benzylisoquinoline alkaloids, stylopine, MG-63, osteosarcoma, VEGFR2
Citation
Frontiers Production Office (2023) Erratum: Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. Front. Pharmacol. 14:1213155. doi: 10.3389/fphar.2023.1213155
Received
27 April 2023
Accepted
27 April 2023
Published
05 May 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
14 - 2023
Updates
Copyright
© 2023 and Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.